Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 54 of 95 for:    body | Recruiting, Not yet recruiting, Available Studies | "Metabolic Syndrome X"

Exercise Training Effects on Metabolic Syndrome: Interactions With Medication (METSYND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03019796
Recruitment Status : Recruiting
First Posted : January 13, 2017
Last Update Posted : May 9, 2017
Sponsor:
Collaborator:
Ministerio de Economía y Competitividad, Spain
Information provided by (Responsible Party):
University of Castilla-La Mancha

Brief Summary:
To analyze the effects of different exercise training modalities (continuous, intervallic, and resistance training) on cardiorespiratory and metabolic fitness of metabolic syndrome patients when this training interacts with their habitual medication.

Condition or disease Intervention/treatment Phase
Exercise Therapy Metabolic Syndrome X Cardiorespiratory Fitness Behavioral: EXERCISE TRAINING Behavioral: NO EXERCISE TRAINING Not Applicable

Detailed Description:

Objective: The purpose is to study in a group of adults with metabolic syndrome and obesity, the effects of different modalities of exercise training on cardiorespiratory and metabolic fitness. The main objective is to weight the effects of exercise training separately and in conjunction with the subject's habitual pharmacological treatment to identify the best combination of drug and exercise.

Methods and design: Randomized, pretest-posttest control group experimental design. Project developed in a single center with the collaboration of the regional public health system.

Subjects: Will be referred by their primary care physicians to our study unit. Up to 160 subjects all of them with metabolic syndrome will be recruited (20% women).

Measurements:

  1. Specifically, the investigators, will study cardiovascular adaptations that increase, i) maximal aerobic capacity measured by VO2max, ii) anaerobic and respiratory compensation point ventilatory thresholds, iii) cardiac function measured by assessing cardiac output and stroke volume using the re-breathing technique, iv) arterial stiffness, measured by pulse wave velocity and augmentation index using applanation tonometry (SphygmoCor System), v) central and peripheral blood pressure, and vi) biological markers of endothelial dysfunction using reactive hyperemia with a laser Doppler fluxmeter in central and peripheral blood vessels.
  2. The metabolic adaptations under study will include, i) insulin resistance measured by IVGTT, ii) fat oxidation by indirect calorimetry, iii) intramuscular proteins involved in energetics by percutaneous muscle biopsy and western blots, iv) mitochondria biogenesis by activity of citrate synthase and v) stable-isotopic study of glucose and free fatty acids kinetics in blood (using gas-chromatography mass-spectrometry analysis).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.
Study Start Date : July 2015
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : August 2018


Arm Intervention/treatment
Placebo Comparator: NO EXERCISE TRAINING

The participants of this arm will remain physically inactive (i.e., less than 1 day a week of exercise) during the 4 months of intervention.

The investigators will withhold their medication during 48 h to achieve 2 conditions:

  1. no exercise, no medication.
  2. no exercise, yes medication.
Behavioral: NO EXERCISE TRAINING
REMAINING INACTIVE AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).

Experimental: EXERCISE TRAINING

The participants of this arm will exercise during 4 months (i.e., 3 days a week during 45-60 min) at workloads individualized by percent heart rate of either continuous or intervallic aerobic exercise, with increases in workload as exercise adaptations manifest during training.

The investigators will withhold their habitual medication during 48 h to achieve the following 2 conditions:

c) yes exercise, no medication d) yes exercise, yes medication.

Behavioral: EXERCISE TRAINING
EXERCISE TRAINING AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).




Primary Outcome Measures :
  1. Brachial artery systolic and diastolic pressures. [ Time Frame: 6 months ]
    Determined by using a ECG-gated automated sphygmomanometer (Tango, Suntec Medical, NC., US).

  2. Waist perimeter. [ Time Frame: 6 months ]
    Using calibrated measurement tape at the iliac crest level.

  3. Fasting blood level of glucose, cholesterol HDL, triglycerides, glycosylated hemoglobin and protein C reactive. [ Time Frame: 6 months ]
    Blood lipid profile to detect metabolic syndrome (Alberti et al., Circulation, 2009)


Secondary Outcome Measures :
  1. Maximal oxygen consumption rate during exercise (VO2max). [ Time Frame: 6 months ]
    Index of cardiorespiratory fitness assessed during an incremental cycle-ergometer test using an indirect calorimetry system (AEI, Moxus system, US).

  2. Anaerobic threshold (AT) and respiratory compensation point (RCP). [ Time Frame: 6 months ]
    Determined by changes in ratios between pulmonary ventilation rates and oxygen and carbon dioxide production during the incremental cycle-ergometer test (Wasserman et al., 2005).

  3. Maximal rate of fat oxidation. [ Time Frame: 6 months ]
    Calculated in grams per min during the incremental cycloergometer test wih the use of indirect calorimetry system (AIE, Moxus system, US).

  4. Arterial stiffness by pulse wave velocity (PWV) and augmentation index (AI). [ Time Frame: 6 months ]
    Determined by applanation tonometry in the radial and femoral arteries (SphygmoCor; AtCor Medical; Sydney, Australia).

  5. Peripheral post-occlusion reactive hyperemia. [ Time Frame: 6 months ]
    Index of endothelial function assessed by measuring forearm peak flow after occlusion using a laser Doppler fluxmeter probe (DRT4; Moor Instruments, Axminster, UK).

  6. Insulin sensitivity using intravenous glucose tolerance test (IVGTT). [ Time Frame: 6 months ]
    Infusion of a glucose bolus and blood sampling for the analysis of glucose and insulin following the procedures described by Tura et al., (Diabetologia, 2010)

  7. Body fat. [ Time Frame: 6 months ]
    Determined by dual-energy X-ray absorptiometry (Hologic Serie Discovery Wi QDR, Bedford, US).


Other Outcome Measures:
  1. Rates of appearance, dissapearance of glycerol and palmitate in blood. [ Time Frame: 6 months ]
    Infusion of stable isotope of 13C palmitate and measurement of enrichment in blood of 12/13C palmitate using gas chromatography-mass spectrometry (Hewlett Packard 5971).

  2. Rates of oxidation of plasma and intracellular free fatty acids. [ Time Frame: 6 months ]
    Analysis of enrichment of 13CO2 collected in expired air using isotope ratio-mass spectrometry (IRMS).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Metabolic syndrome patients diagnosed according to the International diabetes federation consensus of 2009 (Alberti, et al., Circulation).
  • 18-65 years old

Exclusion Criteria:

Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise.

  • Respiratory failure
  • Patient ends
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03019796


Locations
Layout table for location information
Spain
University of Castilla-La Mancha (Exercise Physiology Lab) Recruiting
Toledo, Spain, 45071
Contact: Ricardo Mora-Rodriguez, PhD    92526800 ext 5515    ricardo.mora@uclm.es   
Contact: Juan F Ortega, MD, PhD    +3492526800 ext 5515    juanfernando.ortega@uclm.es   
Sub-Investigator: Juan F Ortega, MD, PhD         
Principal Investigator: Ricardo Mora-Rodriguez, PhD         
Sponsors and Collaborators
University of Castilla-La Mancha
Ministerio de Economía y Competitividad, Spain
Investigators
Layout table for investigator information
Principal Investigator: Ricardo Mora-Rodriguez, PhD University of Castilla-La Mancha

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Castilla-La Mancha
ClinicalTrials.gov Identifier: NCT03019796     History of Changes
Other Study ID Numbers: 0112001154 DEP2014-52930-R
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: May 9, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Metabolic Syndrome
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases